CareDx (NASDAQ:CDNA – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05), Briefing.com reports. CareDx had a negative net margin of 16.09% and a negative return on equity of 10.58%. The business had revenue of $80.63 million during the quarter, compared to analysts’ expectations of $81.85 million. During the same period in the prior year, the firm posted ($0.04) EPS. CareDx’s revenue for the quarter was up 8.7% compared to the same quarter last year. CareDx updated its FY 2022 guidance to EPS.
CareDx Trading Up 8.6 %
Shares of NASDAQ:CDNA traded up $2.09 during trading on Friday, hitting $26.39. 1,448,891 shares of the stock were exchanged, compared to its average volume of 799,671. The company has a fifty day moving average price of $23.65 and a two-hundred day moving average price of $31.02. The company has a market cap of $1.40 billion, a PE ratio of -27.78 and a beta of 0.89. CareDx has a 12-month low of $19.34 and a 12-month high of $84.94.
Insider Transactions at CareDx
In related news, Director Grace Colon sold 5,179 shares of CareDx stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $23.01, for a total transaction of $119,168.79. Following the completion of the transaction, the director now directly owns 2,522 shares in the company, valued at approximately $58,031.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.60% of the company’s stock.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
CDNA has been the topic of a number of analyst reports. Stephens initiated coverage on CareDx in a report on Monday, April 25th. They issued an “overweight” rating and a $50.00 price objective on the stock. StockNews.com lowered CareDx from a “hold” rating to a “sell” rating in a research note on Friday, April 8th. One research analyst has rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $63.50.
CareDx Company Profile
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
- Get a free copy of the StockNews.com research report on CareDx (CDNA)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.